

Noah Medical Corporation



Headquarters: Silicon Valley (San Jose, CA)

Sector: Technology (Robotics, AI), Healthcare (MedTech)

Stage & Funding Type: Growth Stage, Private, Last Valuation \$560mm (Sept 2025)

Problem: Traditional robotic and manual surgeries create incisions on patient body, less precise, physician dependent, high surgical complications, and long recovery.

Solution: Noah Medical has the next generation “no hole” endoluminal robotic surgery solution for early diagnosis, treatment, and surgery. Patients using Noah Medical’s robotic solutions have no bleeding outside the body during the surgical procedure, do not have body scars after the procedure, and can go home next day.

Market Opportunity: “No hole” endoluminal surgery is a \$80B TAM market and is rapid growing.

Traction:

- More than 9000 potential lung cancer patients had Noah Medical’s robotic procedures. The robotic procedure volume doubles every year.
- Top ranking US hospitals are purchasing more Noah Medical robots - Cleveland Clinics has 2, INOVA has 3, University of Chicago has 2, etc.
- FDA cleared (March 2023) and NMPA clearance (expected Q1 2025) - International expansion to GCC/MENA, South East Asia regions.

Snapshot of Lead / Notable Investors:

- Aramco P7, Softbank, Tiger Global, Hillhouse, Hongshan, Medtronic, Olympus, Lenovo

Team: Jian Zhang Ph.D. (CEO, Founder), Ivy Li (CFO), Joe Riley (Head of Sales), John Mesebring (Head of Operations/Manufacturing), and leadership with deep experience in medical robotics.

Funding Ask: Seek **\$150mm** Pre-IPO financing to acceleration commercialization, development of pipeline products

Contact Information: Jian Zhang Ph.D. (CEO) jianzhang@noahmed.com WhatApps: 1-650-861-0191

